JP2016521707A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521707A5
JP2016521707A5 JP2016517967A JP2016517967A JP2016521707A5 JP 2016521707 A5 JP2016521707 A5 JP 2016521707A5 JP 2016517967 A JP2016517967 A JP 2016517967A JP 2016517967 A JP2016517967 A JP 2016517967A JP 2016521707 A5 JP2016521707 A5 JP 2016521707A5
Authority
JP
Japan
Prior art keywords
activatable antibody
target
seq
activatable
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517967A
Other languages
English (en)
Japanese (ja)
Other versions
JP6660294B2 (ja
JP2016521707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/040931 external-priority patent/WO2014197612A1/en
Publication of JP2016521707A publication Critical patent/JP2016521707A/ja
Publication of JP2016521707A5 publication Critical patent/JP2016521707A5/ja
Application granted granted Critical
Publication of JP6660294B2 publication Critical patent/JP6660294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517967A 2013-06-04 2014-06-04 活性化可能抗体を結合するための組成物及び方法 Active JP6660294B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361830913P 2013-06-04 2013-06-04
US61/830,913 2013-06-04
US201361919935P 2013-12-23 2013-12-23
US61/919,935 2013-12-23
PCT/US2014/040931 WO2014197612A1 (en) 2013-06-04 2014-06-04 Compositions and methods for conjugating activatable antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020019517A Division JP2020079292A (ja) 2013-06-04 2020-02-07 活性化可能抗体を結合するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2016521707A JP2016521707A (ja) 2016-07-25
JP2016521707A5 true JP2016521707A5 (enExample) 2017-07-20
JP6660294B2 JP6660294B2 (ja) 2020-03-11

Family

ID=51023194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016517967A Active JP6660294B2 (ja) 2013-06-04 2014-06-04 活性化可能抗体を結合するための組成物及び方法
JP2020019517A Pending JP2020079292A (ja) 2013-06-04 2020-02-07 活性化可能抗体を結合するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020019517A Pending JP2020079292A (ja) 2013-06-04 2020-02-07 活性化可能抗体を結合するための組成物及び方法

Country Status (10)

Country Link
US (4) US9517276B2 (enExample)
EP (1) EP3003387A1 (enExample)
JP (2) JP6660294B2 (enExample)
KR (1) KR20160018579A (enExample)
CN (2) CN116063479A (enExample)
AU (2) AU2014274982B2 (enExample)
BR (1) BR112015030514A2 (enExample)
CA (1) CA2913732A1 (enExample)
RU (1) RU2015156888A (enExample)
WO (1) WO2014197612A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
WO2015066279A2 (en) * 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
SG11201604664PA (en) 2013-12-12 2016-07-28 Stemcentrx Inc Novel anti-dpep3 antibodies and methods of use
CA2939941A1 (en) 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
ES2789351T3 (es) 2015-01-13 2020-10-26 Hope City Máscaras de enlace peptídico de proteínas de unión a CTLA4
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US11045543B2 (en) * 2015-04-06 2021-06-29 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
IL292798A (en) * 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
CN106519037B (zh) * 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
CN105267982A (zh) * 2015-11-20 2016-01-27 暨南大学 一种rhHER2抗体与MMAE偶联物及其制备方法与应用
DK3422845T3 (da) * 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP3454900A4 (en) * 2016-05-09 2020-01-29 Celgene Corporation CD47 ANTIBODIES AND METHODS OF USE
BR112019011564A2 (pt) 2016-12-09 2019-10-22 Seattle Genetics Inc anticorpos bivalentes mascarados por hélices superenroladas
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
JP2021518603A (ja) 2018-03-20 2021-08-02 シートムエックス セラピューティクス，インコーポレイテッド 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
CN108484781B (zh) * 2018-04-23 2021-05-04 深圳市国创纳米抗体技术有限公司 一种纳米抗体与铜绿假单胞菌外毒素的融合蛋白及应用
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
EP3807644A4 (en) * 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
SG11202013248YA (en) 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
WO2020176672A1 (en) * 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
EP4087855A1 (en) * 2020-01-06 2022-11-16 CytomX Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
JP2023521384A (ja) 2020-04-09 2023-05-24 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗体を含む組成物
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
WO2022081541A1 (en) * 2020-10-13 2022-04-21 Chan Zuckerberg Biohub, Inc. Compositions and methods involving antibody constructs
WO2023070353A1 (en) * 2021-10-27 2023-05-04 Adagene Pte. Ltd. Anti-cd47 antibodies and methods of use thereof
JP2025524628A (ja) 2022-07-12 2025-07-30 シートムエックス セラピューティクス，インコーポレイテッド Ｅｐｃａｍイムノコンジュゲート及びその使用
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
JP4942643B2 (ja) * 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
DE602005022928D1 (de) * 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010077643A1 (en) * 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2012131527A1 (en) 2011-04-01 2012-10-04 Wyeth Llc Antibody-drug conjugates
BR112013027119A8 (pt) 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
TWI495644B (zh) * 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
AU2013222935B2 (en) * 2012-02-24 2016-03-10 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
US9856314B2 (en) * 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
EP2863948B1 (en) * 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US20150174265A1 (en) 2012-06-26 2015-06-25 Massachusetts Institute Of Technology Reversible masking of pore-forming proteins for macromolecular delivery
US9487590B2 (en) * 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
US20150290342A1 (en) * 2012-10-24 2015-10-15 Polytherics Limited Drug-protein conjugates
CN105008918A (zh) * 2013-01-04 2015-10-28 西托姆克斯治疗公司 用于检测生物系统中的蛋白酶活性的组合物和方法
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2016521707A5 (enExample)
RU2015156888A (ru) Композиции и методы конъюгирования активируемых антител
JP2022046569A5 (enExample)
JP2022512124A5 (enExample)
US11986535B2 (en) Method of producing an immunoligand/payload conjugate
JP2026004397A5 (enExample)
RU2016135239A (ru) Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения
JP2018504925A5 (enExample)
JP2016525551A5 (enExample)
JP2017509594A5 (enExample)
JP2018520092A5 (enExample)
RU2016106115A (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
JP2016538240A5 (enExample)
HRP20220631T1 (hr) Supstrati koje mogu cijepati matrične metaloproteaze i serinske proteaze, te postupci njihove uporabe
JP2015516813A5 (enExample)
JP2022065174A5 (enExample)
JP2017523176A5 (enExample)
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
HRP20200721T1 (hr) Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
HRP20220172T1 (hr) Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe
JP2020500016A5 (enExample)
CO6180466A2 (es) Composiciones y metodos para diagnosticar y tratar cancer
PE20071055A1 (es) Anticuerpos anti mn
IN2012DN02535A (enExample)